Literature DB >> 19187092

L-DOPA activates ERK signaling and phosphorylates histone H3 in the striatonigral medium spiny neurons of hemiparkinsonian mice.

Emanuela Santini1, Cristina Alcacer, Silvia Cacciatore, Myriam Heiman, Denis Hervé, Paul Greengard, Jean-Antoine Girault, Emmanuel Valjent, Gilberto Fisone.   

Abstract

In the dopamine-depleted striatum, extracellular signal-regulated kinase (ERK) signaling is implicated in the development of L-DOPA-induced dyskinesia. To gain insights on its role in this disorder, we examined the effects of L-DOPA on the state of phosphorylation of ERK and downstream target proteins in striatopallidal and striatonigral medium spiny neurons (MSNs). For this purpose, we employed mice expressing enhanced green fluorescent protein (EGFP) under the control of the promoters for the dopamine D(2) receptor (Drd2-EGFP mice) or the dopamine D(1) receptor (Drd1a-EGFP mice), which are expressed in striatopallidal and striatonigral MSNs, respectively. In 6-hydroxydopamine-lesioned Drd2-EGFP mice, L-DOPA increased the phosphorylation of ERK, mitogen- and stress-activated kinase 1 and histone H3, selectively in EGFP-negative MSNs. Conversely, a complete co-localization between EGFP and these phosphoproteins was observed in Drd1a-EGFP mice. The effect of L-DOPA was prevented by blockade of dopamine D(1) receptors. The same pattern of activation of ERK signaling was observed in dyskinetic mice, after repeated administration of L-DOPA. Our results demonstrate that in the dopamine-depleted striatum, L-DOPA activates ERK signaling specifically in striatonigral MSNs. This regulation may result in ERK-dependent changes in striatal plasticity leading to dyskinesia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19187092     DOI: 10.1111/j.1471-4159.2008.05831.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  73 in total

1.  Role of adrenoceptors in the regulation of dopamine/DARPP-32 signaling in neostriatal neurons.

Authors:  Masato Hara; Ryuichi Fukui; Eriko Hieda; Mahomi Kuroiwa; Helen S Bateup; Tatsuhiko Kano; Paul Greengard; Akinori Nishi
Journal:  J Neurochem       Date:  2010-03-04       Impact factor: 5.372

2.  Enhanced striatal cholinergic neuronal activity mediates L-DOPA-induced dyskinesia in parkinsonian mice.

Authors:  Yunmin Ding; Lisa Won; Jonathan P Britt; Sean Austin O Lim; Daniel S McGehee; Un Jung Kang
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-27       Impact factor: 11.205

3.  Metabotropic glutamate mGluR5 receptor blockade opposes abnormal involuntary movements and the increases in glutamic acid decarboxylase mRNA levels induced by l-DOPA in striatal neurons of 6-hydroxydopamine-lesioned rats.

Authors:  N Yamamoto; J-J Soghomonian
Journal:  Neuroscience       Date:  2009-08-04       Impact factor: 3.590

Review 4.  Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.

Authors:  Mahmoud M Iravani; Peter Jenner
Journal:  J Neural Transm (Vienna)       Date:  2011-09-01       Impact factor: 3.575

5.  Human COMT over-expression confers a heightened susceptibility to dyskinesia in mice.

Authors:  Oscar Solís; Jose-Rubén García-Montes; Patricia Garcia-Sanz; Antonio S Herranz; Maria-José Asensio; Gina Kang; Noboru Hiroi; Rosario Moratalla
Journal:  Neurobiol Dis       Date:  2017-03-16       Impact factor: 5.996

6.  Dopamine D3 Receptor Modulates l-DOPA-Induced Dyskinesia by Targeting D1 Receptor-Mediated Striatal Signaling.

Authors:  Oscar Solís; Jose Ruben Garcia-Montes; Aldo González-Granillo; Ming Xu; Rosario Moratalla
Journal:  Cereb Cortex       Date:  2017-01-01       Impact factor: 5.357

7.  Optogenetic activation of striatal cholinergic interneurons regulates L-dopa-induced dyskinesias.

Authors:  Tanuja Bordia; Xiomara A Perez; Jaime Heiss; Danhui Zhang; Maryka Quik
Journal:  Neurobiol Dis       Date:  2016-02-24       Impact factor: 5.996

8.  Distinct changes in cAMP and extracellular signal-regulated protein kinase signalling in L-DOPA-induced dyskinesia.

Authors:  Emanuela Santini; Veronique Sgambato-Faure; Qin Li; Marc Savasta; Sandra Dovero; Gilberto Fisone; Erwan Bezard
Journal:  PLoS One       Date:  2010-08-23       Impact factor: 3.240

9.  The dopamine metabolite 3-methoxytyramine is a neuromodulator.

Authors:  Tatyana D Sotnikova; Jean-Martin Beaulieu; Stefano Espinoza; Bernard Masri; Xiaodong Zhang; Ali Salahpour; Larry S Barak; Marc G Caron; Raul R Gainetdinov
Journal:  PLoS One       Date:  2010-10-18       Impact factor: 3.240

10.  M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia.

Authors:  Weixing Shen; Joshua L Plotkin; Veronica Francardo; Wai Kin D Ko; Zhong Xie; Qin Li; Tim Fieblinger; Jürgen Wess; Richard R Neubig; Craig W Lindsley; P Jeffrey Conn; Paul Greengard; Erwan Bezard; M Angela Cenci; D James Surmeier
Journal:  Neuron       Date:  2015-11-18       Impact factor: 17.173

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.